Mucosal Delivery of ACNPV Baculovirus Driving Expression of the Gal-Lectin LC3 Fragment Confers Protection against Amoebic Liver Abscess in Hamster by Meneses-Ruiz, DM et al.
Int. J. Biol. Sci. 2011, 7 
 
 
http://www.biolsci.org 
1345 
I In nt te er rn na at ti io on na al l   J Jo ou ur rn na al l   o of f   B Bi io ol lo og gi ic ca al l   S Sc ci ie en nc ce es s   
2011; 7(9):1345-1356 
Research Paper 
Mucosal Delivery of ACNPV Baculovirus Driving Expression of the Gal-Lectin 
LC3 Fragment Confers Protection against Amoebic Liver Abscess in Hamster 
DM Meneses-Ruiz1, JP Laclette 1, H Aguilar-Díaz1, J Hernández-Ruiz3, A Luz-Madrigal2, A Sampieri2, L Vaca2 
and JC Carrero1 
1.  Department of Immunology, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México. A.P. 70228, México 
D.F., México.  
2.  Department of Cell Biology, Instituto de Fisiología Celular,  Universidad Nacional Autónoma de México. A.P. 70228, México D.F., 
México.  
3.  Unit of Experimental Medicine, Facultad de Medicina. Universidad Nacional Autónoma de México. A.P. 70228, México D.F., México.   
 Corresponding author: Tel.: + 52 5556229220; fax: +52 5556223369. E-mail address: carrero@servidor.unam.mx (J.C. Car-
rero) 
© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ 
licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. 
Received: 2011.09.01; Accepted: 2011.10.01; Published: 2011.11.01 
Abstract 
Mucosal vaccination against amoebiasis using the Gal-lectin of E. histolytica has been proposed 
as one of the leading strategies for controlling this human disease. However, most mucosal 
adjuvants used are toxic and the identification of safe delivery systems is necessary. Here, we 
evaluate the potential of a recombinant Autographa californica baculovirus driving the ex-
pression of the LC3 fragment of the Gal-lectin to confer protection against amoebic liver 
abscess (ALA) in hamsters following oral or nasal immunization.   Hamsters immunized by oral 
route showed complete absence (57.9%) or partial development (21%) of ALA, resulting in 
some protection in 78.9% of animals when compared with the wild type baculovirus and sham 
control groups. In contrast, nasal immunization conferred only 21% of protection efficacy. 
Levels of ALA protection showed lineal correlation with the development of an anti-amoebic 
cellular immune response evaluated in spleens, but not with the induction of seric IgG an-
ti-amoeba antibodies. These results suggest that baculovirus driving the expression of E. 
histolytica vaccine candidate antigens is useful for inducing protective cellular and humoral 
immune responses following oral immunization, and therefore it could be used as a system for 
mucosal delivery of an anti-amoebic vaccine. 
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Introduction 
Entamoeba  histolytica  is  a  protozoan  parasite 
which  causes  dysentery  and  amoebic  liver  abscess 
(ALA) disease in humans. It is responsible for 40, 000 
to 100, 000 deaths annually, ranking it as the second 
highest cause of mortality attributed to a protozoan 
parasitic disease (1). In Mexico, amoebiasis is ranked 
as the sixth highest cause of morbidity (2), with the 
last  national  seroepidemiological  survey  showing  a 
seroprevalence  rate  of  8.4%  in  general  population 
using an indirect hemagglutination test (3). Amoebia-
sis  is  most  frequent  in  developing  countries  where 
environmental and population hygiene measures can 
be  deficient.  Although  pharmacological  treatment 
with metronidazole is effective, the still widespread 
prevalence of the disease as well as the side effects 
associated with the drug positions vaccination against 
amoebiasis  an  attractive  alternative  (4).  Ideally,  an 
anti-amoebic vaccine should confer protection against 
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mucosal  colonization  by  the  trophozoites,  avoiding 
intestinal amoebic dysentery, and consequently, the 
extraintestinal ALA disease (5).  
Several candidates for amoebic vaccination have 
been  proposed  by  different  groups  with  a  galac-
tose/N-acetyl-D-galactosamine-inhibitable  lectin 
(Gal-lectin) identified as the leading candidate due to 
its pivotal role in parasite virulence and adhesion to 
the  intestinal  mucosa  (6).  Diverse  studies  have 
demonstrated the potential of native or fractionated 
Gal-lectin protein to confer protection against the de-
velopment of ALA in gerbils using Freund´s complete 
or  incomplete  adjuvants,  Titermax  adjuvant  and/or 
CpG-oligonucleotides,  (7-10).  Similar  results  have 
been  obtained  using  attenuated  Yersinia  and  Salmo-
nella vectors (11, 12) and even, by passive immuniza-
tion with anti-Gal lectin IgG antibodies (13). A frag-
ment  of  the  Gal-lectin  heavy  subunit  named  LC3 
(52kDa),  which  includes  the  carbohydrate-binding 
domain (8), has been shown to be  one  of the  main 
targets for IgG and IgA anti-Gal lectin antibodies re-
covered from patient´s serum and feces, respectively 
(14-16). Using Balb/c mice and non-human primates, 
immunization with cholera toxin-adjuvanted LC3 by 
oral or nasal routes, resulted in elevated serum IgG 
and  fecal  IgA  anti-native  Gal-lectin  antibody  levels 
with the capacity to inhibit E. histolytica trophozoites 
galactose-specific adherence to CHO cells in vitro (17, 
18). In another study, LC3 fragment conferred protec-
tion in gerbils against ALA (71%) following intraper-
itoneal  immunization  before  intraportal  challenge 
with virulent trophozoites (8).  
In  addition  to  inducing  an  effective  local  im-
mune response, oral immunization has also been used 
to  evaluate  the  ability  of  anti-E.  histolytica  vaccine 
candidates to induce protection again extraintestinal 
amoebiasis. Thus, recombinant complete Gal-lectin or 
its  component  fragments  LC3  and  LecA,  the  ser-
ine-rich  protein  SREHP,  the  112  kDa  adhesin 
EhADH112  and  a  30  kDa  protein  belonging  to  the 
collagen-binding proteins familiy, have been shown 
to confer differing levels  of protection  against ALA 
development in hamsters and gerbils following oral 
immunization,  suggesting  a  functional  interaction 
between mucosal and systemic compartments (4, 7-13, 
19-26). However, current limitations associated with 
oral  or  nasal  immunization  in  humans  include  the 
lack of safe mucosal adjuvants. Most adjuvants used 
with animal models in immunization/protection tri-
als are not acceptable for use in humans, including 
Freund´s complete and incomplete adjuvant, cholera 
toxin  (CT)  and  the  attenuated  bacterial  and  yeast 
stocks mentioned previously (11, 12, 22, 24). Thus, the 
search  for  safe  adjuvants  and  optimum  antigen  de-
livery strategies that are capable of inducing effective 
local  protective  immune  responses  against                    
E. histolytica is a matter of fundamental interest. Di-
verse viral vectors have been studied to this end. One 
of  the  most  promising  is  Autographa  Californica,  an 
insect enveloped double-stranded DNA nucleopoly-
hedrovirus (AcNPV) which can drive the expression 
of foreign genes in mammalian cells without causing 
cytotoxic effects (27).  
AcNPV has been shown to possess a strong ad-
juvantig capacity in mammals, promoting enhanced 
humoral  and  cellular  immune  responses  against 
co-administered  antigens.  In  vitro,  AcNPV  induces 
maturation  of  antigen  presenting  cells  (APCs)  and 
production of proinflammatory cytokines and chem-
okines,  via  TLR9/MyD88-dependent  pathways  (28, 
29), supporting its immunogenicity and potential as 
delivery  vaccine  vector.  Numerous  studies  have 
demonstrated that recombinant baculovirus express-
ing target antigens on their surface (baculovirus dis-
play)  and/or  driving  the  cytomegalovirus  (CMV) 
promoter-dependent expression (baculovirus expres-
sion)  confer  protection  against  a  broad  variety  of 
pathogens. Effective immune protection has been re-
ported in murine models using one or both systems 
for several viral and parasitic diseases (30-41).  
In this work we demonstrate for the first time 
protection against the development of ALA in ham-
sters induced by oral immunization with an AcNPV 
baculovirus driving host cell expression of the E. his-
tolytica LC3 Gal-lectin fragment. We  show that oral 
immunization (in the absence of any type of adjuvant) 
using  recombinant  AcNPV  baculovirus  provide  ef-
fective  protection  against  ALA  when  compared  to 
nasal  immunization.  These  results  position  oral  im-
munization  with  LC3-expressing  baculovirus  as  a 
feasible tool for effective vaccination against hepatic 
amoebiasis. 
Materials and methods  
Cells and cultures. Axenic HM1: IMSS tropho-
zoites were maintained in TYI-S-33 medium supple-
mented  with  15%  of  adult  bovine  serum  (Biofluids 
International  Inc.,  MD,  USA)  and  3%  of  Diamond's 
vitamin  mix  (JRH  Biosciences,  Kansas,  USA)  in  an-
aerobic conditions and incubated at 37°C . Trophozo-
ites virulence was maintained trough successive pas-
sages into hamster´s liver and recovering trophozoites 
from the induced ALA.  
sf9  insect  cells  (Spodoptera frugiperda)    (Invitro-
gen, San Diego, CA) were cultivated as monolayer or  
suspension  in    Grace's  medium  (Invitrogen,  USA)   
supplemented with  10%  heat-inactivated fetal bovine 
serum  (Invitrogen,  Carlsbad,  CA),  1%  penicillin/ Int. J. Biol. Sci. 2011, 7 
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streptomycine  (100U/ml)  and  0,1%    pluronic  F-68 
(Invitrogen, USA) and maintained in anaerobic con-
ditions  at  27°C.  Cultures  in  suspension  were  addi-
tionally maintained with constant shaking at 100 rpm. 
HepG2 cells from ATCC were cultivated  in DMEM 
medium  +L-glutamine  (Invitrogen,    USA)  supple-
mented  with  FBS  and  1%  penicillin/streptomycine 
and maintained at 37°C with 5% CO2 and 95%  hu-
midity.  
AcNPV-LC3  baculovirus production.  The  LC3 
coding  region  (amino  acid  773  to  1127)  of  the 
Gal-lectin  heavy  subunit  (8)  was  amplified  from  E. 
histolytica HM1: IMSS DNA using the following pri-
mers:  sense  primer  FLC3HCMV  (5  ' 
TAGAAAGCTTATGTGTTCTAGTTTAACATGTCCA
-3')  and  antisense  primer  RSLC3XCMV  (5  ' 
TTTTTCTAGATTAACATGTTTTCTTTGTGTAAATA
G-3'). The PCR product was cloned into Hind III/XbaI 
sites of plasmid pBlueCMV (42) to generate the con-
struct pBlueCMV-LC3. The LC3 product and the con-
struct were checked for integrity of the ORF by se-
quencing  in  an  automatic  sequencer  ABI-Prism  2.0. 
The  recombinant  baculovirus  AcNPV-LC3  was    
generated by recombination of the CMV-LC3 cassette 
with  AcNPV  DNA  following  the  manufacturer´s    
instructions of the Bac-N-Blue Transfection Kit (Invi-
trogen, Carlsbad, CA). Recombinant AcNPV-LC3 was 
identified  by  reconstitution  of  the  lacZ  gene  and 
β-galactosidase expression determined by addition of 
5-bromine-4-chlorine-3-indolil--D-galactoside 
(X-gal) (150 g/ml) to  infected sf9 cell supernatants. 
Viral  DNA  was  isolated  from  positive  supernatant 
following  the  manufacturer´s  instructions  of  the 
Bac-N-Blue  Transfection  Kit  (Invitrogen,  Carlsbad, 
CA). Presence of the LC3 fragment was confirmed by 
PCR  amplification  and  its  sequence  confirmed  by 
DNA sequencing. 
Recombinant AcNPV-LC3 baculovirus was am-
plified by infecting sf9 insect cells at a multiplicity of 
infection (MOI) of 0.1 and purifying them from cul-
ture´s supernatants 6 days after infection by centrif-
ugation at 6,000 g for 15 min at 4°C. Afterwards, bac-
ulovirus was concentrated by ultracentrifugation in a 
SW28 rotor (Beckman) at 141, 000 g and 4°C during 90 
min,  resuspended  in  PBS,  loaded  onto  a  10–50% 
(wt/vol)  sucrose  gradient  and  centrifuged  at  same 
conditions.  Finally,  the  virus-containing  interphase 
layer  was  collected,  diluted  in  PBS,  centrifuged  as 
before and the pelleted virus titered by using a plaque 
assay  following  the  manufacturer´s  instructions 
(Invitrogen). Wild type virus (AcNPV-WT) was am-
plified and titered following the same protocol as for 
AcNPV-LC3.  
HepG2  cells  transduction  and  Western  blot-
ting. HepG2 cells (1x105) were transducted with 0.1 
MOI of AcNPV-LC3 and analyzed for LC3 expression 
by Western blotting on cellular extracts obtained at 48 
h post-transduction. Shortly, total extract (50g/well) 
was run on denaturalized SDS-PAGE and the protein 
transferred  to  nitrocellulose  membranes  by  electro-
phoresis. Blotted membranes were blocked with 3% 
BSA during 2 h at room temperature and incubated 
with a rabbit polyclonal anti-Gal-lectin heavy subunit 
antiserum  (kindly  provided  by  Rosario  López,      
Unidad de Medicina Experimental, Facultad de Me-
dicina,  UNAM)  during  1  h  at  37  °C.  After  three 
washes  with  PBS-Tween  20,  the  membrane  was  in-
cubated with an HRP-conjugated anti-rabbit IgG an-
tibody (Zymed laboratories, San Francisco, CA. USA) 
during  1  h  at  37°C.  Finally,  the  membrane  was 
washed  as  before  and  the  immune  complexes  re-
vealed by chemiluminescence using ECL Plus West-
ern  Blotting  Detection  System  kit  (GE  Healthcare). 
The antibodies were used to 1:1000 dilution. 
Immunization  and  challenge  protocols.  Male 
Syrian golden hamsters (Mesocricetus auratus) 4 to 6 
weeks of age were maintained free of pathogens with 
water and food ad libitum. Following a protocol ap-
proved by the Institutional Animal Care Committee, 
animals were divided in 6 groups of 19 hamsters each: 
two  non-treated  groups  (non-infected  and  infected 
sham groups) and four immunized groups. Immun-
ized groups comprised two by oral route with WT (O 
AcNPV-WT)  or  LC3  recombinant  (O  AcNPV-LC3) 
baculovirus and two groups by nasal route with WT 
(N  AcNPV-WT)  and  LC3  recombinant  (N  Ac-
NPV-LC3)  baculovirus.  Light  anesthetized  hamsters 
were administered with three dosis at two weeks in-
tervals with 1x108 PFU prepared in 200 l 0.2M Na-
HCO3, pH 8.3 for oral and in 20 l PBS, pH 7.4 for 
nasal  deliveries.  Oral  administration  was  done  by 
using a neonatal feeding tube in previously Sevorane 
sedated  animals,  whereas  nasal  administration  was 
done by releasing 10 l per each nostril using a pi-
pette. Infected sham group received in the same ani-
mals 200 l of NaHCO3 and 20 l of PBS by oral and 
nasal  route,  respectively.  Two  weeks  after  the  last 
immunization,  all  animal,  except  the  non-infected 
sham group, were infected by intra-portal route with 
virulent  E. histolytica  trophozoites.  In  brief,    animal 
were  anesthetized  with  sodium  pentobarbital  (50 
mg/kg; Anestesal, Pfizer) , a laparatomy  practiced in 
aseptic conditions in order to expose the portal vein 
and 106 trophozoites in 100 l PBS were directly in-
jected (43). The site of injection was immediately ob-
truded by applying a gel foam pad, intestine carefully 
returned to the abdominal cavity, and the abdominal Int. J. Biol. Sci. 2011, 7 
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layers sutured with surgical staples (Reflex 9, USA). 
Blood samples were collected from all animals before 
treatment  (day  0)  and  after  immunization  prior  to 
challenge (day 35). Sera were obtained by centrifuga-
tion and stored at -70 °C until use.     
Liver histology. Seven days after the challenge, 
hamsters  were  sacrificed  under  anesthesia  and  the 
liver excised. General liver damage was recorded by 
macroscopic features, weight, distribution and size of 
abscesses. Coronal cuts from whole liver were fixed in 
4%  formaldehyde-PBS  during  24  h,  whereas  others 
fragments were included in Tissue Freezing Medium 
(Leica) and cut in 10  for Hematoxylin-Eosin stain-
ing.  
Antibodies determination by ELISA. Ninety six 
well plates were coated overnight with 5 ng/well of 
trophozoite´s total extract in carbonate buffer, pH 9.6 
at 4°C. After blocking with 1% BSA-Tween 20, ham-
ster´s sera diluted in 1% BSA (1:50) were added to the 
wells  and  incubated  1  h  at  37°C.  After  extensive 
washings with PBS-Tween 20, a HRP-conjugated an-
ti-hamster IgG antibody (Becton Dickinson, USA) was 
added to 1:1000 dilution and incubated for 1 h at 37°C. 
Finally,  the  wells  were  washed  and  the  anti-
gen-antibody  complexes  were  developed  with  OPD 
and read at 490nm in a spectrophotometer.  
Spleen  cells  proliferation  by  flow  cytometry.  
After  sacrifice  at  7  days  post-challenge,  hamster´s 
spleens  were  removed  and  its  cellular  fraction  ob-
tained by perfusion in supplemented RPMI medium. 
The white cells, mostly lymphocytes, were cultivated 
at  105 cells/well in 96-well plates in RPMI medium 
alone or stimulated with concanavalin A (1 g/well), 
or amebic total extract  (50 g/well), at 37°C with 5% 
CO2 and 95% humidity for 72 h. Finally, cells were 
harvested and fixed with formaldehyde at 3.7 %. All 
the treatments were carried out by triplicate for each 
animal.  Samples  were  analyzed  on  a  FACSCanto  II 
flow  cytometer  (BD).  A  minimum  of  20,000  events 
were collected and analyzed with the DIVA software 
from  the  instrument´s  manufacturer.  Proliferation 
data from each experimental group was obtained by 
pooling  the  means  of  the  triplicate  for  each  animal 
and is presented as mean  SD. 
Statistical  analysis.  The  comparison  of  the  in-
fection rates between the immunized groups and their 
respective sham controls was done using Fisher’s ex-
act test. The Kruskal-Wallis test was used to compare 
antibody levels between groups. A P value < 0.05 was 
considered  statistically  signiﬁcant  in  these  analyses. 
All  statistical  analyses  were  performed  using  SPSS 
statistical software version 19.0. 
Results 
Mammalian cells transduced with recombinant 
baculovirus  AcNPV-LC3  efficiently  expressed  LC3 
protein. The baculovirus AcNPV-LC3 was generated 
co-transfecting  the  transference  plasmid  pBlue-
CMV-LC3 (Fig. 1A) with linear DNA of AcNPV in sf9 
insect cells. Purified recombinant viral particles were 
used  to  examine  the  capacity  of  recombinant  bacu-
lovirus for driving the expression of LC3 in HepG2 
mammalian  cells.  Western  blot  on  48  h  transduced 
cells  using  an  anti-Gal-lectin  polyclonal  antibody, 
showed  recognition  of  a  band  with  a  molecular 
weight of approximately 50 kDa, which correspond to 
the expected weight for LC3 (Fig. 1B lane 3). WB on 
non-transduced  HepG2  cells  did  not  recognize  any 
elements when tested with the anti-Gal/GalNac an-
tibody (Fig. 1B lane 2). 
Oral and nasal immunization with AcNPV-LC3 
protects  hamsters  of  developing  ALA.  Hamsters 
randomly divided into 6 groups were immunized by 
mucosal delivery (oral and nasal) with AcNPV-WT, 
AcNPV-LC3  or  NaHCO3/PBS,  before  intraportally 
challenged with virulent trophozoites. Animals were 
sacrificed 7 days after infection, as illustrated in Fig. 
1C. 
In order to evaluate the level of protection in re-
lation  to  development  of  ALA,  we  documented  a 
comparative  macroscopic  description  of  livers  from 
all experimental groups (massive, partial and absence 
of abscesses). Thus, 11 out of 19 O AcNPV-LC3 and 4 
out of 19 N AcNPV-LC3 immunized hamsters did not 
show  any  macroscopic  evidence  of  ALA  develop-
ment,  suggesting  sterile  protection  in  these  animals 
(Table 1). In contrast, numerous ALA covering most 
of the liver´s four lobes tissue were clearly evident in 
all  non-immunized  sham  animals  (19  out  of  19)  as 
well as in all animals (14 out of 14) immunized with 
the WT baculovirus (not carrying the LC3 gene) by 
nasal route and almost all animals (17 out of 19) im-
munized with WT baculovirus by oral route (Table 1). 
Same level of ALA development was observed in the 
other 15 N AcNPV-LC3 and 4 out of 8 O AcNPV-LC3 
non-protected  hamsters.  In  the  other  four  O  Ac-
NPV-LC3  immunized  animals,  differences  in  ALA 
development were observed when comparing sham 
and  WT  controls.  In  general,  abscesses  were  more 
localized (mostly in one lobe) and smaller, suggesting 
partial protection. Percentages of protected, partially 
protected  and  non-protected  animals  are  shown  in 
Fig. 2A. These differences in ALA development were 
also observed when comparing the liver weight of all 
experimental  groups,  because  ALA  development  is 
directly related to hepatomegaly. On average, a liver 
weight  of  6  grams  was  observed  in  O  AcNPV-LC3 Int. J. Biol. Sci. 2011, 7 
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immunized animals, whereas in animals immunized 
with N AcNPV-LC3 an average of 9 grams was ob-
served. These values were significantly smaller when 
compared  to  the  sham  group  (15  g,  p<0.001  and 
p<0.005; Fig. 2B). Moreover, average liver weight of 
the O AcNPV-LC3 group was also different from the 
O AcNPV-WT group (mean of 12 gr; p<0.005) but not 
different from the uninfected non-treated group (5gr) 
(Fig.  2  B).  Also,  no  statistical  differences  in  liver 
weight between the N AcNPV-LC3 group and its re-
spective WT group were observed.  
Macroscopical  observations  were  confirmed 
through liver section analysis. Thus, no tissue damage 
or  trophozoites  were  observed  in  sections  from  the 
liver of the 11 orally and 2 nasally AcNPV-LC3 im-
munized hamsters as well as the 2 orally AcNPV-WT 
immunized  animals  with  sterile  protection  (Fig.  3, 
inset A and B). In contrast, extensive necrosis in all 
lobes with tissue liquefaction and scattered trophozo-
ites  were  observed  in  all  sham  and  N  AcNPV-WT 
animals as well as in all N AcNPV-LC3 and O Ac-
NPV-WT unprotected hamsters (Fig. 3, Insets E to H).  
The four O AcNPV-LC3 partially protected hamsters 
showed a considerable reduction in the number and 
spreading of abscesses (≤ 20% of liver parenchyma) as 
well as in the number of trophozoites (Fig. 3, inset C 
and D).  
Considering  that  orally  administered  WT  Ac-
NPV  conferred  protection  at  10.5%,  the  protection 
efficacy of AcNPV-LC3 administed by this route was 
calculated  in  57.9%,  a  value  statistically  significant 
regarding  sham  and  O  AcNPV-LC3  WT  groups 
(p<0.05 by Fisher´s test; Table 1). Instead, partial pro-
tection was observed in 21% of the animals (4 out of 
19  hamsters)  from  the  O  AcNPV-LC3  group,          
indicating  that  at  least  68.4%  of  the  animals           
immunized by this route developed some protection. 
In  contrast,  nasally  administered  AcNPV-LC3  only 
conferred  sterile  protection  in  21%  of  challenged 
hamsters, with no partial protection observed (Table 1 
and Fig. 2A).  
 
Figure 1. Functional characterization of the recombinant AcNPV-LC3 baculovirus and schedule of im-
munization. AcNPV-LC3 baculovirus was generated by cloning the sequence of the E. histolytica Gal-lectin LC3 fragment 
into the pBlueCMV transfer plasmid downstream of the CMV promoter sequence (A). Ability of AcNPV-LC3 to drive the 
expression of LC3 in mammalian cells was carried out by Western blot on transduced HepG2 cells extract using a rabbit 
polyclonal anti-Gal-lectin heavy subunit antiserum. A band of the expected LC3 molecular weight of 50 kDa was observed 
in the transduced cells (B, line 3). No band was observed in non-transduced cells extract (B, line 2). Details on schedule 
immunization (oral and nasal routes), intraportal challenge with amoeba and sacrifice of hamsters is shown in C.   Int. J. Biol. Sci. 2011, 7 
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Figure 2. Macroscopical evaluation of protection from ALA challenge in hamsters immunized with Ac-
NPV-LC3. After sacrifice, hamster´s livers were exscinded and analyzed for the presence of ALA and hepatomegaly. 
Percentage and number of infected (open bars), partially protected (ALA in < 20% of the whole tissue; black filled bars) and 
sterilizing protection (no evidence of ALA; grey filled bars) for each experimental group is shown in A. Sterilizing protection 
was observed in AcNPV-LC3 immunized animals, mainly for oral  (O) in comparison with nasal (N) routes. Slight sterilizing 
protection was observed in hamsters receiving WT baculovirus for oral route (O AcNPV-WT). Partial protection was only 
observed in O AcNPV-LC3.  Hepatomegaly recorded as the whole liver weight is shown in B. Bar for each group represents 
the mean ± SD (standard deviation) of liver´s weigh of all animals assayed. Statistical differences between the oral and nasal 
AcNPV-LC3 immunized hamsters and the WT and sham control animals are shown (* p < 0.05; ** p < 0.005; *** p < 0.001).     
 Int. J. Biol. Sci. 2011, 7 
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Figure 3. ALA development and hepatic damage analysis in AcNPV-LC3 immunized hamsters after chal-
lenge with E. histolytica. Representative pictures of the three levels of ALA development observed in hamsters of the O 
AcNPV-LC3 group, completely protected (sterilizing protection, A), partially protected (C) and non-protected (E).  For 
comparative purposes, one representative liver from an animal of the sham group is shown in G. Hematoxylin-eosin stained 
section from each liver is shown in B, D, F and H, respectively. Healthy liver tissue with no trophozoites was observed in the 
completely protected hamsters (A and B), in contrast with local (partially protected; C and D) and spread (unprotected; E 
to H) abscesses, where necrotic focus with multiple trophozoites (*) surrounded by inflammatory infiltrates (arrow), are 
usually observed. Yellow bars: 100 µm.   
 
Table 1. Infection rate in AcNPV-LC3 immunized  and untreated control  hamsters intraportally infected with E. histolytica 
trophozoites. 
Groups  Infection Rate (Infected/Total)  
% 
p-value  (Fisher’s Test)  Protection Efficacy (%) 
Sham   19/19 
100% 
NA  0 
O AcNPV-WT  
  
17/19 
89.5% 
0.005  
(vs O AcNPV-LC3) 
10.5 
O AcNPV-LC3 
  
8/19 
42.1% 
0.0001  
(vs Sham)  
57.9 
N AcNPV-WT   14/14 
100% 
0.1192  
(vs N AcNPV-LC3)  
0 
N AcNPV-LC3   15/19 
79% 
0.1 
(vs Sham) 
21 
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Oral  and  nasal  vaccination  with  AcNPV-LC3 
induces  high  levels  of  systemic  anti-amoeba  anti-
bodies.    Systemic  antibodies  raised  against  LC3  by 
immunization with the recombinant baculovirus were 
determined by ELISA in pre and post-immune sera 
collected  from  all  hamsters.  High  titer  of  an-
ti-trophozoite antigen IgG antibodies was observed in 
serum  from  O  AcNPV-LC3  and  N  AcNPV-LC3 
groups after immunization; in contrast to the respec-
tive oral and nasal WT immunized groups which did 
not  developed  IgG  antibodies  recognizing  amoeba 
extracts (p<0.001 for oral groups and p<0.005 for the 
nasal groups comparisons; Fig. 4A, open bars).  
 
 
Figure 4. Humoral and cellular anti-E. histolytica immune responses in AcNPV-LC3 immunized and chal-
lenged hamsters. A. IgG antibodies in sera against total extract of E. histolytica trophozoites were measured by ELISA at 
day 0 (pre-immune sera, filled bars) and 7 days prior to intraportal challenge with trophozoites (day 35; post-immune sera, 
open bars). Bars represent mean optical densities (n = 19). High level of specific IgG antibodies were detected only in sera 
from LC3 immunized animals, independent of the route of immunization (**p < 0.005; *** p < 0.001). B. Cellular immune 
response was evaluated in splenocytes at the day of sacrifice (day 49) by staining of the harvested cells with CFSE and 
stimulation with E. histolytica total extract during 72 h. Bars represent mean of percentage of proliferation of the number of 
hamsters include in each classification. Specific proliferation was only observed in the protected animals, independent of the 
route of immunization (**p < 0.005; *** p < 0.001). Int. J. Biol. Sci. 2011, 7 
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Sera from the AcNPV-LC3 immunized hamsters 
by both routes recognized a band around 170 kDa in 
amoebic total extract by Western blot, suggesting that 
antibodies specific against LC3 and therefore, for the 
Gal-lectin heavy subunit were induced in the animals 
(data not shown). No systemic response was observed 
in the sham and uninfected control groups (p<0.001 
when  comparing  with  AcNPV-LC3  immunized 
groups). These result of high level of IgG antibodies in 
hamsters  immunized  by  both  routes  with  no  clear 
differences between them, suggest that anti-LC3 IgG 
antibodies may be only partially responsible for pro-
tection against ALA, as clear differences in the level of 
protection  between  the  oral  and  nasal  AcNPV-LC3 
immunized groups were observed (Table 1 and Fig. 
2A).   
Oral  and  nasal  vaccination  with  AcNPV-LC3 
induces  cell-mediated  immune  responses.           
Immunization-based  lymphocyte  priming  was  de-
termined in all animals by assaying spleen cells pro-
liferation upon stimulation with E. histolytica tropho-
zoite´s extracts.  As shown in Fig. 4B, all protected 
animals  (sterile  and  partial)  by  immunization  with 
AcNPV-LC3 showed high proportion of proliferating 
cells upon exposition to trophozoite´s antigens, inde-
pendent of the route of immunization. Mean prolifer-
ation values of 15% and 22% of the total population 
for  the  oral  and  nasal  route  respectively  were  ob-
served in the animals with sterile protection.  Mean 
proliferation of 13% of the total population was also 
observed for the partially protected animals by oral 
route. In contrast, only cellular background prolifera-
tion  was  observed  in  the  unprotected  AcNPV-LC3 
and WT immunized hamsters, including the two O 
AcNPV-WT  protected  hamsters  (p<0.005  comparing 
protected  O  AcNPV-LC3  versus  unprotected  O  Ac-
NPV-LC3  and  O-AcNPV-WT  groups;  p<0.001  com-
paring  protected  N  AcNPV-LC3  vs  unprotected  N 
AcNPV-LC3  and  N-AcNPV-WT  groups).  Similar 
background  proliferation  was  also  found  for  sham 
and uninfected control groups (Fig. 4B).  These results 
suggest that protection against ALA in hamsters by 
mucosal immunization with baculovirus driving the 
expression of LC3, was partially dependent on anti-
bodies but strongly dependent on the induction of a 
specific cellular immune response in spleen.        
Discussion 
E. histolytica Gal-lectin has been shown to play an 
important role in parasite colonization, cytotoxicity, 
complement resistance and encystment.  Capable of 
activating  dendritic  cells  and  macrophages  in  vitro, 
the  Gal-lectin  is  also  an  immunodominant  antigen 
recognized  by  sera  from  patients  carrying  amoebic 
infections (16, 44). The combination of these factors 
poses  E. histolytica  Gal-lectin  as  the  leading  vaccine 
candidate against human amoebiasis (45). In the pre-
sent work, we show for the first time that oral and 
nasal immunization of hamsters with the baculovirus 
A. californica driving the expression of the immuno-
genic  E. histolytica  Gal-lectin  heavy  chain  LC3  frag-
ment resulted in the induction of systemic humoral 
and  cellular  anti-LC3  immune  responses  that  con-
ferred  protection  against  ALA.    Protection  was  ob-
served at two levels: i) sterilizing protection, with no 
evidence of macroscopic or microscopic lesions and 
no liver trophozoites, observed in 57.9% and 21% of 
hamster groups immunized with O AcNPV-LC3 or N 
AcNPV-LC3,  respectively  (Table  1);  and  ii)  partial 
protection, with reduction in ALA sizes and weights, 
observed  in  the  O  AcNPV-LC3  immunized  group 
(21%; Fig. 2A and Table 1). Sterilizing protection ob-
served in the O AcNPV-LC3 group suggests that the 
adaptive immune response elicited upon immuniza-
tion, measured as anti-amoeba IgG antibodies in sera 
and spleen cells proliferation, was sufficient to avoid 
early colonization of liver tissue by trophozoites upon 
challenge.  These results are evidence of immune re-
call and thereof immunological memory (46).  How-
ever, complete protection against ALA by both routes 
(17 out of 19 hamsters by oral and 4 out of 19 by nasal) 
was  only  correlated  with  the  lymphoproliferation 
measured from spleens (Fig. 4B) but not with the level 
of anti-amoeba IgG antibodies, as no differences in the 
level of such antibodies were found when comparing 
protected  vs  unprotected  AcNPV-LC3  immunized 
hamsters (Fig. 4A).  
Our protection results agree with those reported 
by  Ivory  and  Chadee  where  gerbils  nasally            
immunized with the Gal-lectin heavy chain and CpG 
oligonucleotides  as  TLR-9  adjuvant  were  protected 
from ALA demonstrating, as we report here, that an 
effective immune response was raised after mucosal 
vaccination. However, in contrast to this report, we 
reached only 21% of sterile protection by nasal  im-
munization whereas they observed partial protection 
before 5 days and almost sterilizing protection at 10 
and 15 days (10). Moreover, in counterpart to our re-
sult  of  AcNPV  adjuvant  activity  conferring  slight 
protection by itself, they observed that CpG-treated 
gerbils developed larger abscesses than those excised 
from  PBS-treated  animals,  suggesting  that  this       
exacerbation could be due to the ability of CpG-ODN 
to  activate  innate  immune  cells  through  TLR9,  a 
mechanism that might be  shared with AcNPV (10). 
Although  the  mechanisms  underlying  these  differ-
ences  are  unknown,  the  different  protection  levels 
could  be  due  to  differences  in  the  animal  model, Int. J. Biol. Sci. 2011, 7 
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trophozoites  virulence  and  adjuvants  used  for  each 
study, as well as to differences in the compartmen-
talization of the induced immune responses. In con-
trol  groups,  low  sterilizing  protection  (10.5%)  was 
only observed in O AcNPV-WT, which showed nei-
ther correlation with spleenocytes response to amoe-
bic  extract  (Fig.  4B)  nor  cross-reactive  antibodies  to 
amoeba (Fig. 4A). The reason for the sterilizing pro-
tection  observed  in  these  two  animals  is  unknown, 
but may be related to poor infection rates during the 
challenge with trophozoites. Protection due to bacu-
lovirus activation of innate immunity is unlikely, be-
cause of the low number of animals protected in the 
WT  control  groups.  Taking  together,  our  study  in 
combination  with  those  the  mentioned  above,  and 
others conferring protection against ALA in gerbils by 
oral immunization  with attenuated bacteria such as 
Yersinia  enterocolitica  and  Salmonella  Typhimurium, 
support the concept that mucosal immunization, and 
particularly  the  oral  route,  as  a  useful  strategy  for 
delivery of an effective anti-amoebic vaccine, not only 
against  intestinal  amoebiasis,  but  also  effective 
against a systemic challenge.  In this sense, oral vac-
cination is considered to be a highly desirable form of 
vaccination,  being  noninvasive,  painless,  and 
self-administrable (47). 
On  the  other  hand,  the  baculovirus-based       
delivery system we used here, may offer an attractive 
immunization strategy because of the low cytotoxicity 
and inability of the virus to replicate in mammalian 
cells (27). Baculovirus are known to efficiently drive 
the expression of foreign proteins in mammalian cells, 
being  currently  used  for  large-scale  production  of 
recombinant  proteins  of  clinical  utility  (48), and  re-
cently proposed as a novel tool for vector-based hu-
man vaccines (49). Since baculovirus can only drive 
the expression of LC3 once inside a cell, our results 
also indicate  that AcNPV administered by oral and 
nasal routes were able to transduce cells with antigen 
presentation  potential,  such  as  local  DCs  or  macro-
phages  in  the  intestinal  submucosa  and  Peyer's 
patches, which in turn processed the LC3 fragment 
and present it to T and B lymphocytes in the draining 
mesenteric  nodes,  resulting  in  the  specific  systemic 
responses and varying degrees of protection observed 
in immunized animals.  However, studies of AcNPV 
cell targeting in immunized hamsters by using labeled 
baculovirus  should  be  carried  out  in  order  to    
demonstrate  in vivo  transduction  of  APC  and  other 
immune cells by the baculovirus. Our results are in 
agreement  with  many  in  vivo  and  in  vitro  studies 
showing  baculovirus  as  potent  adjuvants  by  itself, 
inducing  DCs  maturation  by  TLR9  recognition 
through  MyD88-dependent  and  independent  path-
ways  (28),  and  increasing  its  capacity  of  activate  T 
cells  towards  a  Th1-biased  inflammatory  response 
(50). Previous studies of protection against intestinal 
and  hepatic  amoebiasis  have  used  CT  as  adjuvant 
(51-53), a strong immune elicitor that can induce im-
munological  memory  against  heterologous  antigens 
in most animal models. However, CT is no authorized 
for clinical use in humans due to its enterotoxicity and 
potential  harmful  effects  on  olfactory  nerves  when 
administered nasally (54).  
Mechanisms  underlying  hamster  protection 
against ALA conferred by the oral administration of 
AcNPV-LC3  remain  largely  unknown,  but  correla-
tions with anti-amoeba cellular responses measured 
in the spleen were observed (Fig. 4 A and B).  Pheno-
typic and functional maturation of dendritic cells and 
macrophages  as  well  as  direct  activation  of  B  cells 
induced  by  AcNPV  promotes  antigen  presentation 
and  induction  of  a  Th1  response  and  IgG2a             
antibodies, as shown in numerous studies (28, 29, 50). 
The AcNPV adjuvant effect could be indispensable for 
the  sterilizing  protection  observed  in  the  liver, 
breaking  the  tolerogenic  environment  present  in 
physiological conditions because of exposition to di-
etary  antigens  and  microbe´s  metabolites  that  are 
produced locally, as also occurs in the intestine (55). 
Thus, it has been suggested that during an acute E. 
histolytica infection in the liver parenchyma, the func-
tional activation of iNKT, macrophages and Th1 cells 
is needed to both, control infection and downregulate 
the effect of resident cells such as DCs, Kupffer cells 
and Tregs, whose activation usually induces tolerance 
(56).  Such  mechanism  could  be  present  also  in  the 
intestine, where oral immunization with AcNPV-LC3 
could induce local IgA and cellular immune respons-
es, in addition to the systemic response reported here. 
One  can  speculate  that  a  similar  mechanism  could 
prevent large intestine colonization by E. histolytica, 
therefore preventing development of human intesti-
nal amoebiasis and ALA consequently.   
 Further studies using alternative strategies such 
as protection studies in hamsters and mice passively 
transferred with lymphoid cells from protected ani-
mals may provide sufficient information to identify 
the mechanisms underlying liver and intestine steri-
lizing  protection  by  oral  immunization  observed  in 
this work.   
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